Atopic Dermatitis Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical) and Segment Forecast, 2022-2027

1.1 Atopic Dermatitis Market Snapshot
1.2 Atopic Dermatitis Market- Key Findings

3.1 Disease Overview
3.1.1 ETIOLOGY AND PATHOPHYSIOLOGY
3.1.2 CLASSIFICATION OR STAGING SYSTEMS
3.2 Epidemiology
3.2.1 DISEASE BACKGROUND
3.2.2 RISK FACTORS AND COMORBIDITIES
3.2.3 GLOBAL AND HISTORICAL TRENDS
3.2.4 GLOBAL DATA EPIDEMIOLOGICAL FORECAST METHODOLOGY
3.2.5 EPIDEMIOLOGICAL FORECAST FOR DISEASE AD
3.2.6 DISCUSSION

4.1 Diagnosis and Treatment Overview
4.2 KOL Insights on Disease Management
4.2.1 LONG TERM DISEASE CONTROL (EFFICACY)
4.2.2 TREATMENT APPROACH

5.1 Overview

6.1 Overview
6.2 Lack of Therapeutic Options for Chronic Hand Eczema
6.3 Better Long-Term Disease Control and Management
6.4 More Tolerable Topical Treatment Options
6.5 Improved Patient Treatment Compliance
6.6 Increased Diversity in AD Clinical Trial Recruitment

7.1 Overview
7.1.1 RISE OF THE JAK INHIBITORS
7.1.2 RISE OF INTERLEUKIN-INHIBITING BIOLOGICS
7.1.3 TARGETING NEW SIGNALING PATHWAYS/NOVEL TARGETS
7.2 Clinical Trials Design
7.2.1 CLINICAL TRIAL DESIGN IN AD
7.2.2 CLINICAL TRIAL DESIGN IN CHE

8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 MILD TO MODERATE AGENTS
8.2.2 MODERATE-TO-SEVERE AGENTS

9.1 Overview
9.2 Competitive Assessment
9.2.1 SYSTEMIC AGENTS
9.2.2 TOPICAL AGENTS

10.1 Overview
10.2 Deal-Making Trends

11.1 Atopic Dermatitis Market Structure - PORTER’s Analysis

• Global Atopic Dermatitis PORTER’s Five Force Analysis

12.1 Global Atopic Dermatitis Market
12.2 COVID-19 Impact

13.1 Atopic Dermatitis - Drug Class Deep Dive
13.1.1 CORTICOSTEROIDS
13.1.2 CALCINEURIN INHIBITORS
13.1.3 PDE4 INHIBITORS
13.1.4 BIOLOGICS
13.1.5 OTHER DRUG CLASSES

14.1 Atopic Dermatitis - Route of Administration Deep Dive
14.1.1 INJECTABLE
14.1.2 ORAL
14.1.3 TOPICAL

15.1 Atopic Dermatitis - Regional Deep Dive
15.1.1 NORTH AMERICA
15.1.2 EUROPE
15.1.3 ASIA-PACIFIC
15.1.4 ROW

16.1 Atopic Dermatitis - Market Trends
16.1.1 CONSTANT COMPETITION TO LAUNCH NEW DRUGS
16.2 Atopic Dermatitis - Market Drivers
16.2.1 RISING PREVALENCE OF ATOPIC DERMATITIS
16.2.2 THE RISING DEMAND FOR BIOLOGICS IN ATOPIC DERMATITIS
16.3 Atopic Dermatitis - Market Challenges
16.3.1 INCREASE OF HYPERSENSITIVE REACTION LEADING TO PRODUCT RECALLS
16.3.2 HIGH TREATMENT COST, AND LACK OF REIMBURSEMENT GUIDELINES IN DEVELOPING COUNTRIES.

18.1 Abbreviations
18.2 Methodology
18.3 Key Themes Impacting the Pharmaceutical Industry
18.4 About the Publisher

• Contact the Publisher
• Contact the Publisher

Table 1 Key Trends Overview
Table 2 Research Scope And Segmentation
Table 3 Risk Factors and Comorbidities for AD
Table 4 Treatment Guidelines for AD.
Table 5 Atopic Dermatitis Market
Table 6 Atopic Dermatitis by Products, 2020-2027 ($Mn)
Table 7 Atopic Dermatitis by Route of Administration, 2020-2027 ($Mn)
Table 8 Atopic Dermatitis by Region, 2020-2027 ($Mn)
Table 9 North America Atopic Dermatitis by Country, 2020-2027 ($Mn)
Table 10 Asia-Pacific Atopic Dermatitis by Country, 2020-2027 ($Mn)

Figure 1 Market Snapshot ($Mn)
Figure 2 Key Segment Performance Snapshot
Figure 4 Major Drug Targets for AD Treatment
Figure 5 Major Drug Targets for AD Treatment
Figure 3 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of AD, N, Men and Women, 2020
Figure 4 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of AD, N, All Ages, 2020
Figure 5 7MM, 12-Month Diagnosed Prevalent Cases by Severity, Men and Women, N, All Ages, 2020
Figure 6 Flowchart of the Diagnosis and Management of AD
Figure 7 Overview of the Development Pipeline in AD
Figure 8 Competitive Assessment of Marketed and Pipeline Systemic Drugs Benchmarked Against the SOC, Dupixent
Figure 9 Competitive Assessment of Marketed and Pipeline Systemic Drugs Benchmarked Against the SOC, Dupixent
Figure 10 Global Atopic Dermatitis PORTER’s Five Force Analysis
Figure 11 Global Atopic Dermatitis Market - Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 12 Atopic Dermatitis by Drug Class- Market Overview ($Mn)
Figure 13 Atopic Dermatitis by Drug Class Share - 2021 & 2027 (%)
Figure 14 Corticosteroids Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 15 Calcineurin Inhibitors Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 16 PDE4 Inhibitors Market Revenue Opportunity Forecast, 2020-2027 ($Mn
Figure 17 Biologics Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 18 Other Drug Classes Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 19 Atopic Dermatitis by Route of Administration- Market Overview ($Mn
Figure 20 Atopic Dermatitis by Route of Administration Share - 2021 & 2027 (%)
Figure 21 Injectable Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 22 Oral Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 23 Topical Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 24 Global Atopic Dermatitis by Region- Market Overview ($Mn)
Figure 25 Global Atopic Dermatitis by Region Share - 2021 & 2027 (%)
Figure 26 North America Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 27 Europe Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 28 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 29 ROW Market Revenue Opportunity Forecast, 2020-2027 ($Mn)